This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), UnitedHealth (UNH) and Autolus Therapeutics (AUTL)

Tipranks - Tipranks - Tue Aug 4, 9:26AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rocket Pharmaceuticals (RCKT), UnitedHealth (UNH) and Autolus Therapeutics (AUTL).

Claim 55% Off TipRanks

Rocket Pharmaceuticals (RCKT)

Wedbush analyst Yun Zhong maintained a Buy rating on Rocket Pharmaceuticals today and set a price target of $16.00. The company’s shares closed last Monday at $3.18.

According to TipRanks.com, Zhong is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.6% and a 37.7% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, MoonLake Immunotherapeutics, and Protagonist Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocket Pharmaceuticals with a $11.80 average price target.

See Insiders’ Hot Stocks on TipRanks >>

UnitedHealth (UNH)

In a report released today, George Hill from Deutsche Bank maintained a Hold rating on UnitedHealth. The company’s shares closed last Monday at $415.68.

According to TipRanks.com, Hill is a 5-star analyst with an average return of 8.7% and a 53.5% success rate. Hill covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Elevance Health, and Cardinal Health. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $477.37 average price target, which is a 14.4% upside from current levels. In a report issued on July 19, TD Cowen also maintained a Hold rating on the stock with a $430.00 price target.

Autolus Therapeutics (AUTL)

In a report released today, Matt Phipps from William Blair maintained a Buy rating on Autolus Therapeutics. The company’s shares closed last Monday at $1.89, close to its 52-week low of $1.56.

According to TipRanks.com, Phipps is a 4-star analyst with an average return of 3.3% and a 44.8% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Compass Therapeutics. ;'>

Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $8.08.

Read More on RCKT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).